Avinger Receives FDA Clearance for Patheris Lumivascular Artherectomy System
Avinger, Inc. reported on May 23 that the company has received 510(k) clearance from the FDA for its next-generation Pantheris Lumivascular atherectomy system. Lumivascular is the only technology that combines both real-time intravascular imaging with catheters to treat peripheral artery disease (PAD). This is the first image-guided atherectomy device for the treatment of PAD.
Rocket Tickers alerted subscribers about the news at 8:30 am. The next trade took place at 8:31 am for $1.52. Regular market trading opened for the day at $1.98. After a brief fade at the market open, the stock price continued increasing throughout the day. Avinger closed at $2.23 for a gain of over 46% on the event day.
Visit the Knowledge Center for more information about clinical trials and how to trade them.
Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.
Subscribe here if you would like to start receiving these signals in real-time and start trading!